Comparison of cFos induction by the anxiogenic mGlu2/3 receptor antagonist LY341495 and anxiolytic mGlu2/3 receptor agonist LY354740

被引：0
|
作者：
Schoepp, DD [1 ]
Linden, AM [1 ]
Bergeron, M [1 ]
机构：
[1] Eli Lilly & Co, Neurosci Discovery Res, Indianapolis, IN 46285 USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2004年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [1] mGlu2/3 receptor agonist (LY354740) in anxiety
    Schoepp, Darryle D.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2024, 242
  • [2] Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: Evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo
    Linden, AM
    Bergeron, M
    Schoepp, DD
    [J]. NEUROPHARMACOLOGY, 2005, 49 : 120 - 134
  • [3] Models of anxiety and depression sensitive to the activation of the mGlu2 receptor with the mGlu2/3 agonist LY354740
    Pouzet, B.
    Aerts, N.
    Bouwknecht, J. A.
    Mahieu, M.
    Willems, R.
    Steckler, T.
    [J]. NEUROPHARMACOLOGY, 2008, 55 (04) : 618 - 618
  • [4] LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress
    Schoepp, DD
    Wright, RA
    Levine, LR
    Gaydos, B
    Potter, WZ
    [J]. STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS, 2003, 6 (03): : 189 - 197
  • [5] Effects of mGlu2 or rnGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: Specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus
    Linden, Anni-Maija
    Baez, Melvin
    Bergeron, Marcelle
    Schoepp, Darryle D.
    [J]. NEUROPHARMACOLOGY, 2006, 51 (02) : 213 - 228
  • [6] Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: In vivo pharmacology of LY544344
    Rorick-Kehn, LM
    Perkins, EJ
    Knitowski, KM
    Hart, JC
    Johnson, BG
    Schoepp, DD
    McKinzie, DL
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02): : 905 - 913
  • [7] The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits
    Witkin, J. M.
    Monn, J. A.
    Schoepp, D. D.
    Li, X.
    Overshiner, C.
    Mitchell, S. N.
    Carter, G.
    Johnson, B.
    Rasmussen, K.
    Rorick-Kehn, L. M.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 358 (01): : 71 - 82
  • [8] The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam
    Tizzano, JP
    Griffey, KI
    Schoepp, DD
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 73 (02) : 367 - 374
  • [9] Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist
    Hanna, Lydia
    Ceolin, Laura
    Lucas, Sarah
    Monn, James
    Johnson, Bryan
    Collingridge, Graham
    Bortolotto, Zuner
    Lodge, David
    [J]. NEUROPHARMACOLOGY, 2013, 66 : 114 - 121
  • [10] The mGlu2 (not the mGlu3) receptor mediates the actions of the mGlu2/3 receptor agonist, LY379268, in mouse models predictive of antipsychotic activity
    Woolley, M. L.
    Pemberton, D. J.
    Bate, S.
    Corti, C.
    Jones, D. N. C.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S142 - S142
12345